Healthcare Industry News: Rochester Medical
News Release - February 6, 2018
New Study Finds truFreeze(R) Spray Cryotherapy Less Painful than Radiofrequency Ablation for Treatment of Barrett's Esophagus Related DiseasesLEXINGTON, Mass., Feb. 6, 2018 -- (Healthcare Sales & Marketing Network) -- CSA Medical is pleased to announce that in a multi-center prospective study conducted at three leading academic centers published in the Journal of Clinical Gastroenterology (Liquid Nitrogen Spray Cryotherapy is Associated with Less Postprocedural Pain Than Radiofrequency Ablation in Barrett's Esophagus) investigators found that liquid nitrogen spray cryotherapy (truFreezeŽ) is associated with less post procedural pain than radiofrequency ablation (RFA) in the management of Barrett's esophagus, a condition associated with longstanding acid reflux or GERD. The study, conducted at Virginia Commonwealth University Health, Long Island Jewish Medical Center, and the University of Rochester Medical Center, found that patients undergoing RFA, which uses heat to ablate tissue, had at least five times greater odds of experiencing pain after treatment as compared to patients treated with spray cryotherapy (truFreeze). The study also found that physicians utilizing RFA may be more likely to provide analgesic prescriptions for pain management following the procedure.
"We performed this multi-center study as pain and dysphagia after RFA and liquid nitrogen cryotherapy are not well characterized in prospective studies," according to George Smallfield, MD of Virginia Commonwealth University Health and Arvind Trindade, MD, of Long Island Jewish Medical Center at Northwell Health and member of the Feinstein Institute for Medical Research. "While individual data exists on efficacy of both modalities, there is limited data comparing the side effect profiles of the two ablation methods. Our results will help physicians explain to their patients what to expect after the procedure."
truFreeze liquid nitrogen spray cryotherapy is used for the treatment of Barrett's esophagus, esophageal dysplasia (low and high grade), and esophageal cancer. truFreeze is the only ablation methodology with FDA clearance to treat the complete spectrum of esophageal disease.
"We are very pleased with the outcome of this study, since it confirms what we have consistently heard from physicians and patients related to pain and discomfort following spray cryotherapy for the treatment of esophageal disease," said Ellen Sheets, MD, CEO of CSA Medical, Inc. "Our ability to treat the spectrum of esophageal disease, including low and high grade dysplasia, Barrett's esophagus, and esophageal cancer with less post procedural pain provides patients and their care providers with a favorable alternative treatment option."
About CSA Medical
CSA Medical, Inc. develops and manufactures a proprietary interventional spray cryotherapy technology platform utilizing unique properties of liquid nitrogen spray delivered by a software driven device with specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing. CSA manufactures and distributes this technology in the USA. It is currently used to ablate benign (e.g. Barrett's Esophagus with high grade and/or low grade dysplasia) and malignant lesions.
To learn more about our technology, visit www.csamedical.com. truFreeze is a registered trademark of CSA Medical, Inc.
Source: CSA Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.